Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523588 · ClinicalTrials.gov registry record · Phase 2
Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
A Phase 2 study of Cutaneous Lupus Erythematosus, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00523588 is a Phase 2 study of Cutaneous Lupus Erythematosus that has completed, run by University of Pennsylvania. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00523588, a Phase 2 study of Cutaneous Lupus Erythematosus, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of using the 595 nm Vbeam Perfecta™ flashlamp-excited, pulsed dye laser in this study is to help improve study patients' skin disease. Cutaneous lupus erythematosus (CLE) often presents with disfiguring vascular lesions which are frequently difficult to treat with the available therapeutic measures, such as photoprotection, topical steroids, and antimalarials. Laser therapy provides an alternative treatment option for CLE patients. Although there has been documented experience with laser treatment in CLE patients, no study comparing treated lesions to the natural course of the disease has been conducted.
Conditions Studied
Interventions
- PROCEDURE laser treatment (Candela Vbeam Perfecta™)
Study Locations (1)
Pennsylvania
- University of Pennsylvania, Department of Dermatology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523588
The ClinicalTrials.gov registry entry for NCT00523588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which laser treatment (Candela Vbeam Perfecta™) is the first listed.
NCT00523588 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00523588 about?
NCT00523588 is a clinical study titled "Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser". The purpose of using the 595 nm Vbeam Perfecta™ flashlamp-excited, pulsed dye laser in this study is to help improve study patients' skin disease. Cutaneous lupus erythematosus (CLE) often presents with disfiguring vascular lesions which are frequently difficult to treat with the available therapeut...
What is the current status of trial NCT00523588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-03. Estimated completion is 2010-01.
What conditions does trial NCT00523588 study?
This clinical trial studies the following conditions: Cutaneous Lupus Erythematosus.
What interventions are being tested in trial NCT00523588?
The interventions under investigation include: laser treatment (Candela Vbeam Perfecta™) (PROCEDURE).
Who is sponsoring clinical trial NCT00523588?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00523588 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
COMPLETED · Phase 2
-
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.